header logo image


Page 497«..1020..496497498499..510520..»

Health News Roundup: Trial of rheumatoid arthritis drug in COVID-19 patients; new Ebola outbreak in Congo and more – Devdiscourse

June 16th, 2020 12:46 pm

Following is a summary of current health news briefs.

Explainer: Europe steps up tech battle vs. coronavirus with German app

Germany on Tuesday becomes the latest European country to launch a smartphone app that seeks to break the chain of coronavirus infection by tracking encounters between people and issuing a warning should one of them test positive. A growing number of countries in the region have opted to use Bluetooth short-range radio to measure the risk of exposure, after concluding that tracking people's movements using location data would be intrusive.

Norway to halt COVID-19 track and trace app on data protection concerns

Norway will halt its COVID-19 track and trace app and delete all data collected so far after criticism from the Norwegian Data Protection Authority, the Norwegian Institute of Public Health (NIPH) said on Monday. The app was introduced by some Norwegian authorities to limit the transmission of the coronavirus.

Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients

Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19. The trial is one of several efforts by the U.S. drugmaker to help combat the coronavirus pandemic, which has killed more than 400,000 people globally, according to a Reuters tally.

Up to 17 infected, 11 dead in new Ebola outbreak in Congo

The Democratic Republic of Congo has recorded up to 17 Ebola cases in a new outbreak of the deadly virus in the western province of Equateur, and 11 of those infected have died, medical authorities said on Monday. The authorities had reported 12 infections last week in the central African country, whose dilapidated health system is also combating a measles epidemic that has killed over 6,000 people and COVID-19, which has infected over 4,800 and killed 112.

Chinese capital reinstates curbs as coronavirus resurfaces

Several districts of the Chinese capital put up security checkpoints, closed schools and ordered people to be tested for the coronavirus on Monday after an unexpected spike of cases linked to the biggest wholesale food market in Asia. After nearly two months with no new infections, Beijing officials have reported 79 cases over the past four days, the city's biggest cluster of infections since February.

Russia's coronavirus death toll passes 7,000

Russia on Monday reported 8,246 new cases of the coronavirus, taking the nationwide tally of infections to 537,210, the country's coronavirus crisis response centre said. It said 143 people had died from the virus in the past 24 hours, taking Russia's overall death toll to 7,091.

Crowds gather for coronavirus tests in Beijing amid new outbreak

On a sweltering Beijing afternoon, police vehicles blocked roads near the Guangan Sports Center complex and security guards warned the public to stay clear as residents filed in for testing amid the city's COVID-19 outbreak. Staff in white PPE suits with megaphones yelled directions from gates, telling the crowds to gather in groups according to neighbourhood and avoid touching each other.

Germany's confirmed coronavirus cases rise by 192 to 186,461 - RKI

The number of confirmed coronavirus cases in Germany increased by 192 to 186,461, data from the Robert Koch Institute (RKI) for infectious diseases showed on Monday. The reported death toll rose by four to 8,791, the tally showed.

Mutation in new coronavirus increases chance of infection: study

A specific mutation in the new coronavirus can significantly increase its ability to infect cells, according to a study by U.S. researchers. The research may explain why early outbreaks in some parts of the world did not end up overwhelming health systems as much as other outbreaks in New York and Italy, according to experts at Scripps Research.

France expects AstraZeneca COVID-19 vaccine to be shared pro rata

A deal between AstraZeneca and France over potential COVID-19 vaccines involves doses being split between countries on a pro-rata basis based on population, a source at the French President's office said on Monday. The British drugmaker signed a contract with European governments at the weekend to supply the region with up to 400 million doses of its potential vaccine.

Here is the original post:
Health News Roundup: Trial of rheumatoid arthritis drug in COVID-19 patients; new Ebola outbreak in Congo and more - Devdiscourse

Read More...

Rheumatoid Arthritis Diagnostic Device Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of…

June 16th, 2020 12:46 pm

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Diagnostic Device Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Diagnostic Device, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=170432&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Diagnostic Device manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Diagnostic Device Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Diagnostic Device market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Diagnostic Device market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Diagnostic Device Market, By Product

Rheumatoid Arthritis Diagnostic Device Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=170432&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Diagnostic Device Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Diagnostic Device market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Diagnostic Device Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Diagnostic Device Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Diagnostic Device Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Diagnostic Device Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Diagnostic Device Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Diagnostic Device Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Diagnostic Device Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=170432&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Airport Surveillance Radar Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

AR and VR Smart Glasses Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Business Accounting Software Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the article here:
Rheumatoid Arthritis Diagnostic Device Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of...

Read More...

Rheumatoid Arthritis Therapeutics Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

June 16th, 2020 12:46 pm

New Jersey, United States,- A detailed research study on Rheumatoid Arthritis Therapeutics Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Rheumatoid Arthritis Therapeutics, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=190289&utm_source=COD&utm_medium=888

Leading Rheumatoid Arthritis Therapeutics manufacturers/companies operating at both regional and global levels:

Rheumatoid Arthritis Therapeutics Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Rheumatoid Arthritis Therapeutics market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Rheumatoid Arthritis Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Rheumatoid Arthritis Therapeutics Market, By Product

Rheumatoid Arthritis Therapeutics Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=190289&utm_source=COD&utm_medium=888

Rheumatoid Arthritis Therapeutics Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Rheumatoid Arthritis Therapeutics market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Rheumatoid Arthritis Therapeutics Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Rheumatoid Arthritis Therapeutics Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Rheumatoid Arthritis Therapeutics Market, By Deployment Model

5.1 Overview

6 Rheumatoid Arthritis Therapeutics Market, By Solution

6.1 Overview

7 Rheumatoid Arthritis Therapeutics Market, By Vertical

7.1 Overview

8 Rheumatoid Arthritis Therapeutics Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Rheumatoid Arthritis Therapeutics Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=190289&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Cannabis Extract Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cocoa Butter Equivalent (CBE) Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Collagen Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Rheumatoid Arthritis Therapeutics Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Read More...

Psoriatic Arthritis Treatment Market Scope Emerging Trends, Analysis and Forecast 2028 – Medic Insider

June 16th, 2020 12:46 pm

Global Psoriatic Arthritis Treatment Market: Overview

The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

Read Comprehensive Overview of Report @https://www.tmrresearch.com/psoriatic-arthritis-treatment-market

Link:
Psoriatic Arthritis Treatment Market Scope Emerging Trends, Analysis and Forecast 2028 - Medic Insider

Read More...

Fact check: A mix of honey and cinnamon may have some health benefits, more studies needed – USA TODAY

June 16th, 2020 12:46 pm

Scientists have long suspected that cinnamon can help prevent blood-sugar spikes and protect against insulin resistance, a risk factor for diabetes. But how, exactly, has remained a mystery.

In a Facebook post, a bottle of golden-colored honey and red-brown cinnamon is held side-by-side. The accompanying text alludes to a treatment drug companies wont like getting around.

It is found that a mix of honey and cinnamon cures most diseases, David Wright posted to Facebookin 2014 in a post that has garnered attention on the platform since late May. In separate paragraphs dedicated to certain diseases and common ailments, heprovides detailed dosages and methods for intake.

Make a paste of honey and cinnamon powder, put it on toast instead of jelly and jam, and eat it regularly for breakfast, Wright advises for heart disease. For arthritis, bladder infections, colds, GI and respiratory issues, longevity and even hearing loss, he recommends mixing varying proportions of the household spice and sweetener with boiling or lukewarm water to drink daily or until symptoms dissipate.

Wrightalso dispenses relevant scientific facts to add a layer of medical authenticity.

A scientist in Spain has proved that honey contains a natural Ingredient which kills the influenza germs and saves the patient from flu, he writes. Constant use of honey strengthens the white blood corpuscles (where DNA is contained) to fight bacterial and viral diseases.

The post has received over a million shares and 70,000 comments, the latter of which have been overwhelmingly positive.

Wow, I knew it helped with some things but I had no idea it helped so many things! Belinda Lee Christian commented.

Some commenters, however, expressed skepticism.

How the heck is hearing related to something you ingest?? Diane Plourde asked.

Wright did not respond to USA TODAY for commentsand clarification.

The use of honey has been well-documented since antiquity, dating as far back as the Stone Age. In the fourth century B.C., the Sumeriansof Mesopotamia, a region once spanning most of modern-day Iraq and eastern Syria, documented the sweet, viscous syrup as both nutritional and medical, even usingit as an ointment. Ancient texts penned by the fathers of early medicine like Aristotle and Hippocrates, as well as Arab and Ayurvedic doctors, also recognized honeys medicinal benefits.

In the last 20 years or so, scientists have uncovered much about this food made by the humble bee.

Bees collect the dilute-sugary nectar of flora plants, produce an enzymatic activity after ingestion, regurgitate it into honey cells and evaporate a high percentage of water out of it, Dana Hunnes, a senior dietitian at Ronald Reagan UCLA Medical Center, explained to Timelast year.

The end product honey consists of simple sugar molecules, mostly fructose and glucose, which can be easilyused by the body for energy.

The rest of honeys chemical composition is made up of enzymes, amino acids, vitamins, calcium, iron, zinc and potassium to name a few. And much of its prized pharmacological effect comes from antioxidants called polyphenols.

These compounds are responsible for some of honeys potential health benefits and part of what distinguishes the sweetener from more traditional ones like sugar, Jenny Friedman, a Philadelphia-based registered dietitian, told Time last year.

Cinnamon, like honey, has also enjoyed a long history. Its first documented use was as a perfuming agent during the ancient Egyptian embalming process. During the Middle Ages, it became known as a useful meat preservativeand a treatment for coughs, arthritis and sore throats.

The much-loved fragrant spice, obtained from the bark of Lauraceae family of trees found in Asia, Australia and South America, contains polyphenols and various other chemical compounds with reported anti-inflammatory, antimicrobial, antidiabetic, anticancer and lipid-lowering properties.

According to the U.S. Department of Agriculture, one teaspoon of ground cinnamon contains 26 mg of calcium, 0.2 mg of iron, less than 1 mg of magnesium and phosphorous each, about 11 mg of potassium and 0.4 micrograms of vitamin A.

More: Best recipes for stress baking during the pandemic, from beginner level to challenging

Many studies involving honey or cinnamon have not focused on their combined action. Thanks to its antimicrobial properties, honey has shown promise in wound care and fighting off catheter-associated UTIs. More rigorous studies are needed to conclude it's helpfulness in alleviating eczema, ringworm or acne but its generally agreed salving on some of the natural sweetenerdoesnt hurt.

Studies have found cinnamon could potentially lower fasting blood glucose and blood pressure in type 2 diabetics. Levels of LDL, total cholesterol and HDL may also improve but are subject to further study. Additionally, cinnamon may protect against stomach ulcers, Alzheimers disease, increase life span, prevent hepatitis C viral entry and improve arthritic pain. Most results are derived from animal models, in vitro studies or from small sample sizes and would require detailed investigation.

The claim of honey and cinnamon for oral hygiene, however, may be substantiated. One 2017 study found that honey and cinnamon appear to work together to fight against Streptococcus mutans, a bacterium known for its role in tooth decay.

There are no studies indicating honey and cinnamon effective in curing hearing loss, fatigue or increasing life span in human subjects. While honey and cinnamon may soothe symptoms of the common cold or the flu, they cannot kill influenza germs (influenza being a virus and not a bacteria) as the Facebook post claims.

There are hundreds of honey types worldwide, with over 300 variations in the United States alone. The benefits of one particular honey can differ from another depending on many factors including the nectars floral source, the environment and even the bees age. New Zealand manuka honey has been well-researched and recognized for its medicinal properties; Tualang honey found in Malaysia and buckwheat honey are also gaining attention. Buyers must beware of imported honey, which can be filtered with other sweeteners like corn syrup thereby reducing its health and nutritional value.

When it comes to cinnamon, it may come as a surprise to learn most supermarket cinnamon is not of the true cinnamon, or Ceylon variety, but cassia, Chinese cinnamon. While both have been used in studies looking at effects on blood glucose, eating too much of cassia cinnamon may be harmful in large doses.

As far as recommended daily dosages of either one, experts recommend consuming no more than a tablespoon of honey or one-quarterto about 1.25 teaspoonsof cassia daily (there are no human studies available yet for optimal dosing with Ceylon cinnamon). Many of the doses prescribed in the Facebook post exceed the recommended limits.

We rate the health claim of honey and cinnamon as a cure for most diseases PARTLY FALSE because some of it was not supported by our research. While its true honey and cinnamon individually may help improve and even protect against some diseases, there is a lack of studies looking at both honey and cinnamon together. There's no scientific evidence backing improving hearing loss and the claim of weight loss may be inferred but has not been confirmed. The prescribed dosages mentioned exceed the recommended daily servings and could be potentially harmful.

Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.

Our fact check work is supported in part by a grant from Facebook.

Read or Share this story: https://www.usatoday.com/story/news/factcheck/2020/06/14/fact-check-health-benefits-honey-and-cinnamon/3175131001/

More here:
Fact check: A mix of honey and cinnamon may have some health benefits, more studies needed - USA TODAY

Read More...

Psoriatic Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

June 16th, 2020 12:46 pm

New Jersey, United States,- A detailed research study on Psoriatic Arthritis Drugs Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Psoriatic Arthritis Drugs, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=201953&utm_source=COD&utm_medium=888

Leading Psoriatic Arthritis Drugs manufacturers/companies operating at both regional and global levels:

Psoriatic Arthritis Drugs Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Psoriatic Arthritis Drugs market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Psoriatic Arthritis Drugs market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Psoriatic Arthritis Drugs Market, By Product

Psoriatic Arthritis Drugs Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201953&utm_source=COD&utm_medium=888

Psoriatic Arthritis Drugs Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Psoriatic Arthritis Drugs market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Psoriatic Arthritis Drugs Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Psoriatic Arthritis Drugs Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Psoriatic Arthritis Drugs Market, By Deployment Model

5.1 Overview

6 Psoriatic Arthritis Drugs Market, By Solution

6.1 Overview

7 Psoriatic Arthritis Drugs Market, By Vertical

7.1 Overview

8 Psoriatic Arthritis Drugs Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Psoriatic Arthritis Drugs Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=201953&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Engineered Fluids Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Seam Tapes Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Interventional Oncology Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Psoriatic Arthritis Drugs Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Read More...

Recovery and complications of stem cell transplants …

June 16th, 2020 12:45 pm

The process is relatively straightforward and will only take between 30mins and 4 hours to complete. You will be carefully monitored during your stem cells infusion.

Your treating team will monitor you very closely in the days following your transplant. They will take your blood often to ensure your body has accepted the new stem cells and the stem cells are doing their job in your bone marrow.

Infections are common after a stem cell transplant due to the high dose therapies you receive in the lead up. If you have a fever (feeling very hot or cold or are shivering) you should alert your doctor or nurse immediately.

Please see Stem Cell Transplants and Infection Prevention for important information for patients and visitors.

There are several conditions that are commonly associated with high dose chemotherapy and radiotherapy, or with the transplant itself. There is also a risk with allogeneic transplant that your new stem cells will not engraft, however this is rare. Your treating team will take every precaution to prevent these and monitor you closely to ensure they are quickly detected and treated.

You treating team will discuss with you at length any complications associated with both autologous and allogeneic stem cell transplantation. If you experience any new symptoms you should alert your doctor or nurses immediately.

Please see Treatment Related Side Effects for other common side effects from treatment.

It will take some time to recover from a stem cell transplant. It varies from person to person and is dependent on your disease, the other treatments you received and any complications you may have experienced.

Generally speaking recovery takes:

When you leave hospital you will still need to return regularly to monitor the progress of your transplant and your general well-being.

If it is a medical emergency call 000

If you have any of the following symptoms please contact Peter Mac straight away and ask for the registrar on call, on (03) 8559 5000:

If you present to an emergency department, please ensure you let them know immediately that you have had a stem cell transplant and do not wait in the emergency cue.

This content was adapted from the Leukaemia Foundation's Guides for Patient and Families.

Here is the original post:
Recovery and complications of stem cell transplants ...

Read More...

2025 Projection: Autologous Stem Cell and Non Stem Based therapies Market 2020 by Product, Application, Manufacturer, Sales and Segmentation 2026 -…

June 16th, 2020 12:45 pm

COVID-19 impact will also be included and considered for forecast.

Global Autologous Stem Cell and Non Stem Based therapies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Autologous Stem Cell and Non Stem Based therapies Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=70&RequestType=Sample

Brandessence Market Research is working on a new report titleAutologous Stem Cell and Non Stem Based therapies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?.Rise in the prevalence of Cancer and Diabetes in all age groups population. Furthermore, the growing geriatric population is another key factor which drives the Autologous Stem Cell and Non Stem Based therapies Market.

Autologous Stem Cell and Non Stem Based therapies Market Reports

Autologous Stem Cell transplantation is a process in which cells from which all blood cells develop are removed, preserved and later given to the same person after severe treatment. In autologous stem cell transplantation, the patient itself acts as stem cell donor. These cells are collected in advance while they are in remission and returned to the patient at a later stage i.e., after two months. They are used to replace stem cells which have been impaired by high doses of chemotherapy.It is important to realize that the processes required in a stem cell transplant are lengthy and complicated. A transplant involves a lot of preparation and a lot of care after procedure. Many people have a single autologous stem cell transplant while othersmainlyhaving myeloma or tumors; have two or more continuous transplants.

The initial step in an autologous stem cell transplant is gathering the stem cells. Physicians usually collect stem cells from the bloodstream (peripheral blood stem cells) in advance. A mobilization treatment is used. When the stem cells are in the bloodstream, then collection process starts.The blood is separated using an Apheresis machine. This procedurerequires a few hours, and is repeated until the appropriate amount of stem cells is collected. Once the stem cells are harvested, they are frozen in our Stem Cell Processing and Cryopreservation Laboratory until its time to transplant.

Autologous Stem Cell and Non Stem Based therapies Market is segmented on the basis of Application, product, End user and Geography. Based upon ApplicationAutologous Stem Cell and Non Stem Based therapies Market is classified as Neurodegenerative Disorders,Autoimmune Diseases, cancer &Tumors, Cardiovascular Diseases and Others. Based on the ProductAutologous Stem Cell and Non Stem Based therapies Market is classified into Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices and Intracranial Pressure Monitoring Devices. On the basis of End users Autologous Stem Cell and Non Stem Based therapies Market is classified into Hospitals, Ambulatory Surgical Centers and Others.

The regions covered in Autologous Stem Cell and Non Stem Based therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Autologous Stem Cell and Non Stem Based therapies Market Reports :Autologous Stem Cell and Non Stem Based therapies Marketreports cover prominent players likeBioheart, Antrie Inc., Virxsys, Brainstorm Cell Therapeutics, TiGenix, Cytori Therapeutics Inc.,Tengion Inc.,Dendreon Corporation, Regeneus, Fibrocell, Genesis Biopharma, Orgenesis, Opexa Therapeutics,Neostem, U.S. Stem Cell Inc.,Vericel Corporation, Sanofi, IovanceBiotherapeutics Inc., Mesoblast Ltd., pluristem, Med Cell Europe AG, Anova IRM Stem Cell Center, Stemedica Cell Technologies Inc.,General Electric Company, BioRestorative Therapies,StemGenexamong,Aastrom Biosciences,NeoStem, Inc.,Virxsys, Genzyme Corporation and Georgia Health Science University.

Autologous Stem Cell and Non Stem Based therapies Market Dynamics

Rising prevalence of cancer and diabetes among people across all age groups, growing geriatric population, increasing demand for autologous stem cell and non-stem cell based therapies is another factor, which is likely to create a heightened demand. Moreover, Favorable reimbursement policies across several nations are also boosting market. Risks and complications associated with the Autologous Stem Cell and Non Stem Based therapy such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility and thehigh cost of autologous cellular therapies ranging from $500,000 to $1,000,000 restraint the market. Innovation of some newtherapies with improved efficacy, fewer side effects are expected to offer good opportunity for growth of Autologous Stem Cell and Non Stem Based therapies Market in the future.

Autologous Stem Cell and Non Stem Based therapies Market Regional Analysis North America is probable to attain the largest share of the Autologous Stem Cell and Non Stem Based therapies Market in terms of revenue and expected to hold the position followed by Europe region. This is due to less risk related with the treatment. Also, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not require an outside donor hence the treatment is less infectious and cheap. However, Asia Pacific is expected to show the high growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Rising healthcare facilities as well as increasing tax and reimbursement procedures is also estimated to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Key Benefits for Autologous Stem Cell and Non Stem Based therapies Market Reports

Autologous Stem Cell and Non Stem Based therapies Market report covers in depth historical and forecast analysis.Autologous Stem Cell and Non Stem Based therapies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Autologous Stem Cell and Non Stem Based therapies Market report helps to identify opportunities in market place.Autologous Stem Cell and Non Stem Based therapies Market report covers extensive analysis of emerging trends and competitive landscape.Autologous Stem Cell and Non Stem Based therapies Market Segmentation Autologous Stem Cell and Non Stem Based therapies Market: By Application AnalysisNeurodegenerative DisordersAutoimmune Diseasescancer & TumorsCardiovascular DiseasesOthersAutologous Stem Cell and Non Stem Based therapies Market: By Product AnalysisBlood Pressure Monitoring DevicesPulmonary Pressure Monitoring DevicesIntracranial Pressure Monitoring DevicesOthersAutologous Stem Cell and Non Stem Based therapies Market: By End User AnalysisHospitalsAmbulatory Surgical centersOthersAutologous Stem Cell and Non Stem Based therapies Market: By Regional & Country AnalysisNorth AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=70&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Autologous Stem Cell and Non Stem Based therapies Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Autologous Stem Cell and Non Stem Based therapies Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Autologous Stem Cell and Non Stem Based therapies Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Autologous Stem Cell and Non Stem Based therapies Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Autologous Stem Cell and Non Stem Based therapies Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Autologous Stem Cell and Non Stem Based therapies Market.

Market Forecast: Here, the report offers a complete forecast of the Global Autologous Stem Cell and Non Stem Based therapies Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Follow this link:
2025 Projection: Autologous Stem Cell and Non Stem Based therapies Market 2020 by Product, Application, Manufacturer, Sales and Segmentation 2026 -...

Read More...

GLOBAL HUMAN EMBRYONIC STEM CELL MARKET Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business…

June 16th, 2020 12:45 pm

With a full devotion and dedication this superior GLOBAL HUMAN EMBRYONIC STEM CELL MARKET report is presented to the clients that extend their reach to success. Market parameters covered in this advertising report can be listed as market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. Each parameter included in this GLOBAL HUMAN EMBRYONIC STEM CELL MARKET business research report is again explored deeply for the better and actionable market insights. Geographical scope of the products is also carried out comprehensively for the major global areas which helps define strategies for the product distribution in those areas.

TheGlobal Human Embryonic Stem Cell Marketstudy with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. The report presents a complete assessment of the Market covering future trend, current growth factors, attentive opinions, facts, and industry validated market data forecast till 2026. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share ofMajor Players such as Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc and amny More

Global human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Avail 20% Discount on Buying This Report: Get a Free Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Global Human Embryonic Stem Cell Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Human Embryonic Stem Cell Industry

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-human-embryonic-stem-cell-market

The titled segments and sub-section of the market are illuminated below:

By Type

By Application

By End User

Top Players in the Market are:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

How will the report help new companies to plan their investments in the Human Embryonic Stem Cell market?

The Human Embryonic Stem Cell market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Human Embryonic Stem Cell Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Human Embryonic Stem Cell Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post:
GLOBAL HUMAN EMBRYONIC STEM CELL MARKET Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business...

Read More...

Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia – Targeted Oncology

June 16th, 2020 12:45 pm

Treatment with plinabulin in combination with pegfilgrastim (Neulasta) achieved the primary end point and several key secondary end points in the phase 3 PROTECTIVE (Study 106) clinical trial, which evaluated the combination compared with pegfilgrastim alone for superiority in chemotherapy-induced neutropenia prevention, according to the interim results announced by BeyondSpring, developer of the drug.

These results demonstrate significant enhancement to granulocyte colony-stimulating factors (G-CSFs) with the combination compared with pegfilgrastim alone for the prevention of grade 4 or severe neutropenia, supporting the potential for superiority with the combination compared with pegfilgrastim alone.

These interim results from the PROTECTIVE-2 Phase 3 study, which compares the Plinabulin-Neulasta combination to Neulasta alone, have the potential to be clinically meaningful for cancer patients receiving chemotherapy, stated Douglas W. Blayney, MD, professor of Medicine at Stanford Medical School and global principal investigator of Plinabulins chemotherapy-induced neutropenia studies. Since most infections, hospitalizations, and other complications of chemotherapy-induced neutropenia occur in the first week after chemotherapy, it is particularly gratifying to see the combinations clinical benefit demonstrated.

The primary end point was the rare of severe neutropenia prevention in cycle 1 (P <.01). The key secondary end points included duration of severe neutropenia in cycle 1 (P <.05) and duration of severe neutropenia in the first 8 days of cycle 1 (P <.05). The achievement of these end points demonstrates the agents ability to provide early protection against severe neutropenia induced by chemotherapy.

The interim analysis of the double-blind, active-controlled, global PROTECTIVE-2 study was pre-specified for the first 120 patients accrued. The study also has procedures in place for the prevention of potential bias after the planned interim analysis, and BeyondSpring opted to be informed by independent statisticians on whether the pre-specified P values were met rather than the exact P values.

The study was designed to assess both the safety and efficacy of plinabulin in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide (TAC) in a 21-day cycle. Plinabulin was administered in a 40 mg dose on day 1 with a 6 mg dose of pegfilgrastim on day 2, while pegfilgrastim was administered at the same 6 mg dose on day 2 in the control arm. TAC is considered a high-risk chemotherapy regimen associated with neutropenia.

PROTECTIVE-2 is a superiority study for chemotherapy-induced neutropenia efficacy compared with pegfilgrastim alone and is currently enrolling patients. Grade 4 neutropenia rate for TAC and pegfilgrastim is observed in 83% to 93% of patients, which represents a severe unmet medical need.

The study drug and G-CSF have complementary mechanisms of action for preventing chemotherapy-induced neutropenia. Plinabulin is a first-in-class differentiated immune and stem cell modulator, which is currently in late-stage clinical development as a potential treatment for increasing overall survival in patients with cancer in addition to its ability to alleviate chemotherapy-induced neutropenia.

Plinabulin is also under evaluation in a phase 3 study as a direct anticancer drug as treatment of patients with nonsmall cell lung cancer and 2 phase 3 studies for the prevention of chemotherapy-induced neutropenia. The data for this agent in preventing chemotherapy-induced neutropenia highlights its ability to boost the number of hematopoietic stem or progenitor cells (HSPcs), as well as lineage-/cKIT+/Sca1+ cells in mice. Plinabulins effects on HSPcs may explain its ability to treat chemotherapy-induced neutropenia as well as its ability to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34-positive cells.

To be included in the study, patients should be candidates for TAC in either the adjuvant or neoadjuvant setting, have early-stage breast cancer, and have received no prior chemotherapy. Patients must also have an ECOG performance status of 0 or 1 and a life expectancy of at least 3 months. Patients cannot be included in the study if they have a history of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease; use of CYP3A4, CYP2D6 or P-glycoprotein inhibitors and inducers within 14 days prior to receiving the study drug; or have received an investigational agent or tumor vaccine within 2 weeks, any concurrent anticancer therapies, or a bone marrow or stem cell transplantation.

These results could help to confirm the patient benefit of Plinabulins different mechanism of action from the G-CSF-based agents, such as Neulasta, Blayney stated. Plinabulin appears to have chemotherapy-induced neutropenia protection in Week 1, and G-CSFs have protection in Week 2 of chemotherapy cycles. The combination should logically provide significantly better protection than Neulasta alone as shown in the interim readout. We are well on our way to confirming that the combination offers protection throughout the chemotherapy cycle, which is an unmet medical need.

Reference

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention. NewsRelease. BeyondSpring. June 15, 2020. Accessed June 15, 2020. https://bit.ly/2YDJbiQ

Read the original post:
Plinabulin Combo May Be Superior Therapy for Prevention of Chemotherapy-Induced Neutropenia - Targeted Oncology

Read More...

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird…

June 16th, 2020 12:45 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for adult and adolescent patients with sickle cell disease (SCD) show a near-complete reduction of serious vaso-occlusive crises (VOCs) and acute chest syndrome (ACS). These data are being presented at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress.

Vaso-occlusive crises (VOCs) are the painful, life-threatening episodes that are the primary clinical manifestation of sickle cell disease. The nearly complete elimination of VOCs that we saw in this study is impressive and demonstrates the potential of LentiGlobin for SCD as a treatment for this serious disease, said David Davidson, M.D., chief medical officer, bluebird bio. These results illustrate the type of outcomes we believe are needed to provide truly meaningful improvements for people living with sickle cell disease. In addition, the improvement of laboratory measures of hemolysis and red cell physiology, with nearly pan-cellular distribution of the anti-sickling HbAT87Q, suggest LentiGlobin for SCD may substantially modify the causative pathophysiology of SCD. We are pleased to have reached a general agreement with the FDA on the clinical data required to support a submission for LentiGlobin for SCD and we plan to seek an accelerated approval. We look forward to working with the entire SCD community to bring forward a disease modifying option for patients.

SCD is a serious, progressive and debilitating genetic disease caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS). HbS causes red blood cells to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and unpredictable, painful VOCs. For adults and children living with SCD, this means painful crises and other life altering or life-threatening acute complicationssuch as ACS, stroke and infections. If patients survive the acute complications, vasculopathy and end-organ damage, resulting complications can lead to pulmonary hypertension, renal failure and early death; in the U.S. the median age of death for someone with sickle cell disease is 43 - 46 years.

As a physician treating sickle cell for over 10 years, the excruciating pain crises that my patients suffer from is one of the most challenging and frustrating aspects of this disease, said presenting study author Julie Kanter, M.D., University of Alabama at Birmingham. The promising results of this study, which show patients have an almost complete elimination of VOCs and ACS, suggest LentiGlobin for SCD has real potential to provide a significant impact for people living with sickle cell disease.

LentiGlobin for SCD was designed to add functional copies of a modified form of the -globin gene (A-T87Q-globin gene) into a patients own hematopoietic (blood) stem cells (HSCs). Once patients have the A-T87Q-globin gene, their red blood cells can produce anti-sickling hemoglobin, HbAT87Q, that decreases the proportion of HbS, with the goal of reducing sickled red blood cells, hemolysis and other complications.

As of March 3, 2020, a total of 37 patients have been treated with LentiGlobin for SCD to-date in the HGB-205 (n=3) and HGB-206 (n=34) clinical studies. The HGB-206 total includes: Group A (n=7), B (n=2) and C (n=25).

HGB-206: Group C Updated Efficacy Results

In Group C of HGB-206, 25 patients were treated with LentiGlobin for SCD and have up to 24.8 months of follow-up (median of 12.1; min.-max.: 2.824.8 months). Results from Group C are as of March 3, 2020 and include efficacy data for 16 patients who had at least a Month 6 visit, and safety data for 18 patients, which includes two patients who were at least six months post-treatment but results from a Month 6 visit are not available.

In 16 patients with six or more months of follow-up, median levels of gene therapy-derived anti-sickling hemoglobin, HbAT87Q, were maintained with HbAT87Q contributing at least 40% of total hemoglobin. At last visit reported, total hemoglobin ranged from 9.6 16.2 g/dL and HbAT87Q levels ranged from 2.7 9.4 g/dL. At Month 6 the production of HbAT87Q was associated with a reduction in the proportion of HbS in total hemoglobin. Patients had a median of 60% HbS. All patients in Group C were able to stop regular blood transfusions and remain off transfusions at three months post-treatment.

There was a 99.5% mean reduction in annualized rate of VOC and ACS among the 14 patients who had at least six months of follow-up and a history of VOCs or ACS, defined as four or more VOC or ACS events in the two years prior to treatment. These 14 patients had a median of eight events in the two years prior to treatment (min.-max.: 4 28 events).

There were no reports of serious VOCs or ACS at up to 24 months post-treatment in patients with at least six months of follow-up (n=18). As previously reported, one non-serious Grade 2 VOC was observed in a patient approximately 3.5 months post-treatment with LentiGlobin for SCD.

In sickle cell disease, red blood cells become sickled and fragile, rupturing more easily than healthy red blood cells. The breakdown of red blood cells is hemolysis and this process occurs normally in the body. However, in sickle cell disease hemolysis happens too quickly due to the fragility of the red blood cells, which results in hemolytic anemia.

Patients treated with LentiGlobin for SCD demonstrated improvement in key markers of hemolysis, which are indicators of the health of red blood cells. Lab results assessing these indicators were available for the majority of the 18 patients with 6 months of follow-up. The medians for reticulocyte counts (n=15), lactate dehydrogenase (LDH) levels (n=13) and total bilirubin (n=16) improved compared to screening and stabilized by Month 6. In patients with Month 24 data (n=5) these values approached the upper limit of normal by Month 24. These results suggest treatment with LentiGlobin for SCD is improving biological markers of sickle cell disease.

Assays were developed by bluebird bio to enable the detection of HbAT87Q and HbS protein in individual red blood cells as well as to assess if HbAT87Q was pancellular, present throughout all of a patients red blood cells. Samples from a subset of patients in Group C were assessed. In nine patients who had at least six months of follow-up, the average proportion of red blood cells positive for HbAT87Q was greater than 70%, and on average more than 85% of red blood cells contained HbAT87Q at 18 months post-treatment, suggesting near-complete pancellularity of HbAT87Q distribution.

HGB-206: Group C Safety Results

As of March 3, 2020, the safety data from all patients in HGB-206 are generally reflective of underlying SCD and the known side effects of hematopoietic stem cell collection and myeloablative conditioning. There were no serious adverse events related to LentiGlobin for SCD, and the non-serious, related adverse events (AEs) were mild-to-moderate in intensity and self-limited.

One patient with a history of frequent pre-treatment VOE, pulmonary and systemic hypertension, venous thrombosis, obesity, sleep apnea and asthma had complete resolution of VOEs following treatment, but suffered sudden death 20 months after treatment with LentiGlobin for SCD. The patients autopsy revealed cardiac enlargement and fibrosis, and concluded the cause of death was cardiovascular, with contributions from SCD and asthma. The treating physician and an independent monitoring committee agreed this death was unlikely related to LentiGlobin for SCD gene therapy.

The presentation is now available on demand on the EHA25 website:

About HGB-206

HGB-206 is an ongoing, Phase 1/2 open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for SCD that includes three treatment cohorts: Groups A (n=7), B (n=2) and C (n=25). A refined manufacturing process that was designed to increase vector copy number (VCN) and improve engraftment potential of gene-modified stem cells was used for Group C. Group C patients also received LentiGlobin for SCD made from HSCs collected from peripheral blood after mobilization with plerixafor, rather than via bone marrow harvest, which was used in Groups A and B of HGB-206.

LentiGlobin for Sickle Cell Disease Regulatory Status

bluebird bio reached general agreement with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of patients in the HGB-206 study Group C that have already been treated. The planned submission will be based on an analysis using complete resolution of severe vaso-occlusive events (VOEs) as the primary endpoint with at least 18 months of follow-up post-treatment with LentiGlobin for SCD. Globin response will be used as a key secondary endpoint.

bluebird bio anticipates additional guidance from the FDA regarding the commercial manufacturing process, including suspension lentiviral vector. bluebird bio announced in a May 11, 2020 press release it plans to seek an accelerated approval and expects to submit the U.S. BLA for SCD in the second half of 2021.

About LentiGlobin for Sickle Cell Disease

LentiGlobin for sickle cell disease is an investigational gene therapy being studied as a potential treatment for SCD. bluebird bios clinical development program for LentiGlobin for SCD includes the ongoing Phase 1/2 HGB-206 study and the ongoing Phase 3 HGB-210 study.

LentiGlobin for SCD received orphan medicinal product designation from the European Commission for the treatment of SCD.

The U.S. FDA granted orphan drug designation, regenerative medicine advanced therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for SCD.

LentiGlobin for SCD is investigational and has not been approved in any geography.

bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-303) for people who have participated in bluebird bio-sponsored clinical studies of betibeglogene autotemcel for -thalassemia or LentiGlobin for SCD. For more information visit: https://www.bluebirdbio.com/our-science/clinical-trials or clinicaltrials.gov and use identifier NCT02633943 for LTF-303.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders, including cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using three gene therapy technologies: gene addition; cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash., Durham, N.C., and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

bluebird bio Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the companys development and regulatory plans for the LentiGlobin for SCD product candidate, and the companys intentions regarding the timing for providing further updates on the development of the product candidate. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the COVID-19 pandemic and resulting impact on our operations and healthcare systems will affect the execution of our development plans or the conduct of our clinical studies; the risk that even if LentiGlobin for SCD addresses ACS and VOC events, that it may not address progressive organ damage experienced by patients with SCD; the risk that the efficacy and safety results observed in the patients treated in our prior and ongoing clinical trials of LentiGlobin for SCD may not persist or be durable; the risk that the efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in when treating additional patients in our ongoing or planned clinical trials; the risk that the HGB-206 and HGB-210 clinical studies as currently contemplated may be insufficient to support regulatory submissions or marketing approval in the United States and European Union; the risk that regulatory authorities will require additional information regarding our product candidate, resulting in a delay to our anticipated timelines for regulatory submissions, including our application for marketing approval. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Visit link:
New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird...

Read More...

37 Scientists Embarking on Innovative Biomedical Research – The Pew Charitable Trusts

June 16th, 2020 12:45 pm

As the COVID-19 pandemic unfolds around the world, the call for cutting-edge research is louder than ever. Human health has become a top priority for scientists, policymakers, and the public, inspiring investment in vaccines and other novel solutions to the most complicated biomedical questions.

For 35 years, The Pew Charitable Trusts has supported risk-taking among early career biomedical scientists. This year, 37 researchers join the Pew Scholars Program in the Biomedical Sciences,the Pew Latin American Fellows Program in the Biomedical Sciences, andthe Pew-Stewart Scholars Program for Cancer Research, receiving multiyear grants to pursue scientific interests in the United States and Latin America.

The 2020 scholars and fellows are embarking on groundbreaking research projects (visit our research pagesfor more) designed to advance human health at a time when the world needs scientific ingenuity the most

Disease, caused by viral and bacterial infections and environmental triggers, poses a serious threat to public health. The immune system is the human bodys best line of defense against illness, and researchers in this years class will investigate how various immune factors work together to help thwart disease.

The influenza virusknown as the flucan lead to other health complications, including secondary bacterial pneumonia. To uncover why this occurs, one researcher will assess how the flu alters the function of immune and lung cells to increase susceptibility to pneumonia.

HIV can also hide quietly inside humans and infect their immune cells, where the virus can remain dormant for a long period. However, the virus is known to emerge once a persons immunity weakens. One researcher will explore how this occurswork that may help to treat HIV and AIDS.

To better grasp the trajectory of diseases, researchers will also examine how environmental factorssuch as diet, sleep, and stressinfluence an animals ability to manage inflammatory chemicals during infection. By looking at how inflammation can trigger future infections and increase vulnerability to other diseases such as cancer and diabetes, researchers hope to uncover new treatment approaches.

Several researchers in the 2020 class will investigate human development and aging through the lens of gene activation, cellular function, and immunity.

Female mammals are born with a stockpile of oocytes, or egg cells, with mechanisms that protect them from protein deterioration and metabolic imbalances before fertilization. One researcher will evaluate this process, aiming to help slow or prevent the fertility clock from expiring.

Maternal antibodies found in a mothers milk play an important role in early childhood development, helping infants to metabolize nutrients and protecting them from infection. These antibodies also foster beneficial gut bacteria, and one researcher will identify microbial species in the gut that help to regulate growthwork that could help address infant malnutrition.

Finally, scientists have observed that females typically live longer than males. To understand why, one researcher will assess whether sex-based differences in immunity affect the way we age. Researchers will also examine how cells remove toxic proteins, compartmentalize nutrients, and maintain the health of the mitochondria as we agework that may inform how to extend healthy life spans and enhance the way we live.

Cancer, characterized by the uncontrolled growth of abnormal cells in the body, is a complex disease that takes on many forms. Several researchers will explore how to better detect, prevent, and defend against this devastating disease.

To improve cancer detection methods, one researcher will examine unique sequences from cell-free DNAwhich is shed by tumorsto help identify abnormal gene patterns associated with certain stages or types of cancers. This work could help devise a cheaper and more sensitive blood test to detect cancer.

Breast cancer affects about 2.1 million women globally each year. By investigating how normal cellular processes go awryfor example, how certain protein building blocks or RNA molecules are incorrectly modified during the development of breast cancerresearchers hope to identify new targets for small molecule drugs that could halt cancers growth and spread.

Cancers have also found unique ways to survive and thrive in the human body. For example, leukemia stem cells evade detection by cloaking themselves with proteins that render them invisible to the immune system. This years cancer researchers will investigate the many ways in which cancer resists therapy and is able to recur.

The brain is made up of more than 100 billion nerves that control all bodily functions and interpret signals from the outside world. Several researchers in this years class will inspect its structure and explore how it drives complex behaviors.

To analyze how different regions of the brain cooperate to make decisions, researchers will study how animals filter information from their surroundings and generate an appropriate behavioral response. For instance, one researcher will examine how an infants brain senses hunger and directs the child to cry out for food.

To better grasp how the brain develops, researchers will use single-cell technologies to construct a family tree of the human cerebral cortexthe brains outer layerand then determine whether any branches of this cerebral family tree are missing or altered in people with autism or schizophrenia.

Finally, after identifying the neural circuits in the brain that regulate sugar cravings, researchers will assess whether artificially activating these sugar-sensing circuits can elevate mood, or if suppressing them triggers depression and anxietywork that could develop new mental health therapies.

Kara Coleman directs The Pew Charitable Trusts biomedical programs, including the biomedical scholars, Pew-Stewart Scholars for Cancer Research, and Latin American fellows programs,and Jennifer Villa is a principal associate supporting the programs.

Read more from the original source:
37 Scientists Embarking on Innovative Biomedical Research - The Pew Charitable Trusts

Read More...

2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 – Cole of Duty

June 16th, 2020 12:45 pm

COVID-19 impact will also be included and considered for forecast.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Thalassemia Treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Thalassemia Treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Thalassemia Treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Thalassemia Treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Thalassemia Treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Thalassemia Treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Thalassemia Treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Thalassemia Treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Continued here:
2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 - Cole of Duty

Read More...

Global Induced Pluripotent Market Revenue Opportunities and Analysis with Key Players Thermo Fisher Scientific; Cell Applications, Inc.; Axol…

June 16th, 2020 12:45 pm

The Induced Pluripotent report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2026. The data included in this Induced Pluripotent report provides detailed information of the geographic landscape, competitive scenarios and upcoming opportunities in the Industry. The inclusion of the statistical records in the Induced Pluripotent report helps in authenticating the results that are being presented and thus provide a clear vision and indication to clients in understanding the response of the participants.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-market

Few of the major competitors currently working in the induced pluripotent market areBristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Segmentation: Global Induced Pluripotent Market

By Product Category

By Cell Type

By Application

By End-User

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-market

Key Developments in the Market:

Market Restraints

Table of Contents

1. Introduction2. Market Segmentation3. Market Overview4. Executive Summary5. Premium Insights6. Global, By Component7. Product Type8. Delivery9. Industry Type10. Geography

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-induced-pluripotent-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

More here:
Global Induced Pluripotent Market Revenue Opportunities and Analysis with Key Players Thermo Fisher Scientific; Cell Applications, Inc.; Axol...

Read More...

Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech – Endpoints News

June 16th, 2020 12:45 pm

A Wayne, PA-based startup called NFlection has raised $20 million in their Series A launch round. F-Prime and venBio Partners provided the cash for the rare disease biotech, funding their first clinical trial for NFX-179 Gel in adult patients with cutaneous neurofibromatosis type-1, or NF-1. This study allows us to determine the drugs ability to suppress key biomarkers involved in the progression of neurofibromas and will aid in the selection of doses for a larger Phase2bstudy, saidCEO Christopher Powala.

Having steered an idiopathic pulmonary fibrosis drug to a big-money deal with Gilead, Galapagos has enlisted e-therapeutics and its silico phenotypic screening platform to discover some new approaches to modulating a specific mechanism involved in IPF and possibly other fibrotic diseases. The Oxford biotech will be responsible for the computational activities while Belgium-based Galapagos performs the experimental testing.

BryoLogyx has forged a pair of agreements with Neurotrope. The company agreed to acquire Neurotropes preclinical data and drug product for use of bryostatin-1 in an immuno-oncology application and to supply synthetic bryostatin-1 for use in clinical trials and potential commercialization for the treatment of Alzheimers disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a cooperative research and development agreement with the National Cancer Institute. They didnt disclose financial terms.

California-based drug developer Rezolute has bagged the FDAs pediatric disease designation for RZ358, its mid-stage drug for congenital hyperinsulinism. The disease, characterized by excess insulin secretion, causes repeated episodes of low blood sugar. The condition often goes unnoticed in infants, putting them at risk of complications of recurring hypoglycemic events, including developmental delays, seizures, coma and death.

Read this article:
Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech - Endpoints News

Read More...

Karyopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

June 16th, 2020 12:45 pm

Karyopharm Doses First Patient in Brain Cancer Trial

Karyopharm Therapeutics (KPTI) announced that it has dosed the first patient for its Phase 1/2 clinical trial. The study aims to assess the potential of oral Selinexor in combination with standard of care therapy in treating patients suffering from newly diagnosed or recurrent glioblastoma. This multi-site study is expected to enroll nearly 400 patients in clinical sites spread across the United States, Europe and Israel.

The randomized Phase 1/2 study is scheduled to be conducted in two phases. The Phase 1 study is mainly aimed at determining dosage, while the Phase 2 randomized efficacy exploration trial aims to independently assess three different combination regimens in three treatment arms in patients with newly diagnosed GBM (Arms A and B) or with recurrent GBM (Arm C). Arms A and B will examine Selinexor in conjunction with radiation therapy with or without temozolomide. Arm C aims to assess the potential of Selinexor and lomustine.

The primary endpoint of the Phase 1 study is to determine the maximum tolerated dose and the recommended dose to be given in the second phase trial. Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm, said, While selinexor has been most extensively studied in patients with hematologic malignancies, there is increasing evidence that selinexor may also play an important role in the treatment of a variety of solid tumors, including patients with GBM. Phase 2 study will have the primary endpoints of progression-free survival in patients with newly diagnosed GBM and overall survival (OS) in patients with recurrent GBM.

Selinexor is an oral selective inhibitor of the nuclear export (SINE) compound. The compound is known to block the cellular protein XP01, which plays an important role in controlling various tumor suppressor proteins as well as other relevant oncoproteins. In its previous studies, the drug candidate has shown the ability to cross the blood-brain barrier. In a Phase 2 KING study, aimed to assess Selinexor as a single agent in patients with recurrent GBM, it showed robust anti-cancer activity.

Selinexor is already approved by the FDA as a treatment for patients with relapsed or refractory multiple myeloma. It is currently the only FDA-approved XP01 inhibitor and has two additional supplemental New Drug Applications under review by the FDA. The first application seeks label extension for the drug candidate to include its use in treating patients with multiple myeloma after at least one prior line of therapy. The second application pertains to the treatment of patients suffering from relapsed or refractory diffuse large B-cell lymphoma. The drug candidate is in the market under the brand name XPOVIO.

Karyopharm mainly focuses on developing therapies for treating different cancers and other major diseases.

Dynavax (DVAX) announced that it has completed the process of enrolment for its Heplisav-B Phase 1 clinical trial. The company expects the final immunogenicity data to be available by Q4. Dynavax has enrolled 119 patients for the study, which aims to evaluate the drug candidate in adult patients suffering from end-stage renal disease who are starting or already undergoing hemodialysis.

HBV-24 is an open-label, single-arm study which is designed to evaluate a new 4-dose regimen of HEPLISAV-B. The patients enrolled in the study have not previously been treated with a hepatitis B vaccine. Robert Janssen, MD, Chief Medical Officer at Dynavax. We are evaluating a 4-dose regimen of HEPLISAV-B in this study, which we believe may provide an important hepatitis B vaccination alternative for adults with end-stage renal disease on dialysis. We look forward to a scientific presentation of the final data at an appropriate forum in the future. Hepatitis B is a viral disease of the liver and may lead to other complications such as liver cancer and cirrhosis.

The trial aims to assess the drug candidates immunogenicity at study week 20 and safety over the 68-week study duration. Safety and effectiveness of HEPLISAV-B have yet to be established in adults on hemodialysis. The hepatitis B virus is highly infectious, and there is no cure for this. However, the disease may be prevented by effective vaccination. Adults may contract the infection through various means, including infected blood transfusion.

HEPLISAV-B combines hepatitis B surface antigen with Dynavaxs proprietary Toll-like Receptor (TLR) 9 agonist CpG 1018. The drug candidate works by boosting the immune response in a patient. It is indicated for preventing infection caused by all known subtypes of hepatitis virus. HEPLISAV-B is currently only prescribed to adults 18 years or older.

BeyondSpring (BYSI) reported positive data from its PROTECTIVE-2 Phase 2 superiority trial. The study aims to test the potential of Plinabulin, the companys lead drug candidate, in treating breast cancer.

PROTECTIVE-2 assessed the superiority potential of the drug candidate in preventing chemotherapy-induced neutropenia in breast cancer patients treated with docetaxel, doxorubicin and cyclophosphamide. The patients were administered 20mg/m2 of Plinabulin combined with 6mg of Neulasta. The control group was given 6mg of Neulasta alone. The data showed that the combination improved compliance with targeted chemotherapy. It enabled more patients to take the optimal chemotherapy dose and regimen.

None of the patients in combination group downgraded chemotherapy from the TAC regimen to the TC regimen, whereas 18.2 percent patients in the control cohort had to downgrade. Dr. Ramon Mohanlal, BeyondSprings Chief Medical Officer and EVP, R&D, said, This approach provides potential benefits for both clinicians and patients: clinicians may gain greater control over cancer care, and patients may experience better clinical outcomes and an improved quality of life. The improvement in the prevention of Grade 4 neutropenia that is seen with the Plinabulin-Neulasta combination is even more important in todays healthcare environment due to the devastating impact of COVID-19 on immune-suppressed patients. The company plans to release interim top line data from the Phase 3 trial in the near future.

Plinabulin is a differentiated immune and stem cell modulator. The drug candidate is currently in late-stage clinical development phase for treating cancer and to alleviate chemotherapy-induced neutropenia. The drug mainly acts as an antigen presenting cell inducer and aids T-cell activation. In combination, of Plinabulin and G-CSF play complementary roles in reducing CIN. PROTECTIVE-2 is a superiority study and pits the combination against Neulasta. Apart from Plinabulin, BeyondSpring has three immune-oncology product candidates in its development pipeline. It also has a drug discovery platform which uses the ubiquitination degradation pathway.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Original post:
Karyopharm Brain Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Read More...

GM seeds: the debate, and a sowing agitation – The Indian Express

June 15th, 2020 6:50 am

Written by Parthasarathi Biswas | Pune | Updated: June 12, 2020 12:56:06 pm Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. (File Photo)

Last week, Shetkari Sanghatana the farmers union founded by the late leader Sharad Joshi announced fresh plans in its agitation for use of genetically modified seeds. In the current kharif season, farmers would undertake mass sowing of GM seeds for maize, soyabean, mustard brinjal and herbicide tolerant (Ht) cotton, although these are not approved. Farmers had carried out a similar movement last year, too.

What are genetically modified seeds?

Conventional plant breeding involves crossing species of the same genus to provide the offspring with the desired traits of both parents. Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. The alien gene could be from a plant, an animal or even a soil bacterium.

Bt cotton, the only GM crop that is allowed in India, has two alien genes from the soil bacterium Bacillus thuringiensis (Bt) that allows the crop to develop a protein toxic to the common pest pink bollworm. Ht Bt, on the other, cotton is derived with the insertion of an additional gene, from another soil bacterium, which allows the plant to resist the common herbicide glyphosate.

In Bt brinjal, a gene allows the plant to resist attacks of fruit and shoot borer.

In DMH-11 mustard, developed by Deepak Pental and colleague in the South Campus of University of Delhi, genetic modification allows cross-pollination in a crop that self-pollinates in nature.

Across the world, GM variants of maize, canola and soyabean, too, are available.

What is the legal position of genetically modified crops in India?

In India, the Genetic Engineering Appraisal Committee (GEAC) is the apex body that allows for commercial release of GM crops. In 2002, the GEAC had allowed the commercial release of Bt cotton. More than 95 per cent of the countrys cotton area has since then come under Bt cotton. Use of the unapproved GM variant can attract a jail term of 5 years and fine of Rs 1 lakh under the Environmental Protection Act ,1989.

Why are farmers rooting for GM crops?

In the case of cotton, farmers cite the high cost of weeding, which goes down considerably if they grow Ht Bt cotton and use glyphosate against weeds. Brinjal growers in Haryana have rooted for Bt brinjal as it reduces the cost of production by cutting down on the use of pesticides.

Unauthorised crops are widely used. Industry estimates say that of the 4-4.5 crore packets (each weighing 400 gm) of cotton sold in the country, 50 lakh are of the unapproved Ht Bt cotton. Haryana has reported farmers growing Bt brinjal in pockets which had caused a major agitation there. In June last year, in a movement led by Shetkari Sanghatana in Akola district of Maharashtra, more than 1,000 farmers defied the government and sowed Ht Bt cotton. The Akola district authorities subsequently booked the organisers.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Environmentalists argue that the long-lasting effect of GM crops is yet to be studied and thus they should not be released commercially. Genetic modification, they say, brings about changes that can be harmful to humans in the long run.

What is the movement about?

The Sanghatana has announced that this year they are going to undertake large-scale sowing of unapproved GM crops like maize, Ht Bt cotton, soyabean and brinjal across Maharashtra. Farmers who plant such variants will put up boards on their fields proclaiming the GM nature of their crop. Anil Ghanwat, president of the union, has said this action will draw attention to the need for introduction of the latest technology in the fields. He said farmers will not be deterred by any action taken against them by the authorities.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Read the original post:
GM seeds: the debate, and a sowing agitation - The Indian Express

Read More...

Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease – Silicon Canals

June 15th, 2020 6:50 am

Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organisms genome. Gene editing could be a powerful tool for helping people suffering from chronic ailments. Some companies are working tirelessly to employ gene editing for solving health problems and Cambridge, Massachusetts based Verve Therapeutics is one of them. The company has now secured 56M in Series A2 to advance gene-editing therapies for reducing the risk of coronary heart disease.

The latest series A2 round for Verve Therapeutics was led by companys existing investor GV, which was formerly known as Google Ventures. Furthermore, current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital also joined the investment round. New investors Wellington Management and Casdin Capital also joined in. With the latest funding, the overall funds raised by the company touch a total of 109.5 million.

Coronary heart disease is said to be one of the leading causes of death in the U.S. and worldwide. Verve capital is developing a solution to tackle the issue and lower its risks in adults. It is doing so by developing one-time, gene-editing therapies that can safely edit targeted genes in the liver, which will result in permanent lowering of LDL cholesterol and triglycerides, which are key risk factors causing coronary heart disease. With the freshly acquired funds, the company will focus on advancing its lead program through IND-enabling studies and progress follow-on pipeline programs.

We are immensely grateful to our existing investors for their continued support and commitment to our bold vision to eradicate coronary heart disease, and are very pleased to welcome Wellington Management and Casdin Capital to our investor syndicate, says Sekar Kathiresan, M.D, co-founder and CEO of Verve. This financing is a testament to the tremendous work by the Verve team and will position us to rapidly advance our lead therapeutic candidate through IND-enabling studies and expand our pipeline of development programs. People with heart disease are in urgent need of new therapeutic options, and Verves research to date further underscores the transformative potential of gene editing as a therapeutic approach for these patients.

Image credits: Verve Therapeutics

Stay tuned toSilicon Canalsfor more European technology news

The rest is here:
Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease - Silicon Canals

Read More...

How Receptive are Consumers to Agricultural Biotech? – Food Institute Focus – Food Institute Blog

June 15th, 2020 6:50 am

After decades of being sidelined by consumers concerned over whether they were safe, foods made with genetically modified organisms, or GMOs, may finally find a place on more meal plates along with other new agricultural biotechnologies aimed at making plants drought- or flood-tolerant and increasing yields.

The changing climate and growing population are pressuring the food system, experts said. At the same time younger generations like Gen Z are interested in the environment and sustainability and are more likely to be open to eating food created with new technologies that could boost yields.

Consumers should think less about the technology and more about what we can do to enhance the sustainability of agriculture, said Pamela Ronald, PhD, professor in the department of plant pathology at the University of California at Davis. There will be different technologies, now and into the future. There is a critical challenge to feed the growing population without destroying the environment.

Dr. Roland and her colleagues developed a rice that can withstand the heavy flooding in Africa and Asia and increase yields. She coauthored a paper entitled Crop Biotechnology and the Future of Food that appeared in the May 19 issue of Nature Food on genetic tools to help increase food production.

By 2050 the global population is predicted to reach 9.7 billion. Meeting this higher food demand, if consumption practices and food waste do not change, requires estimated food production increases of 25% to 200%, she wrote. Cultivated crops using food technologies are part of the solution, she said.

Meanwhile, anti-GMO groups including the Organic Consumers Association in Finland, MN, and the Institute for Agriculture and Trade Policy in Minneapolis, MN, argue there isnt enough research yet on GMOs to assure they are safe to eat.

Some companies even use a non-GMO label as an advantage when marketing to consumers. Meat alternative company Beyond Meat utilized that label to distinguish itself from competitor Impossible Burger, which uses two genetically engineered ingredients: soy leghemoglobin and soy protein.

However, debates over GMO or non-GMO labeling are unlikely to fundamentally change consumers views of GMOs, said William Hallman, PhD, professor and chair of the Department of Human Ecology at Rutgers University, New Brunswick, NJ.

Sales of the Impossible Burger dont appear to be flagging because people are concerned about the fact that it has GMO-based ingredients, he said. In fact, it is more likely that people are attracted to the idea that both the Beyond and Impossible burgers are plant-based, which creates a health halo around the products.

He mentioned most consumers will freely admit they know little about GMOs or gene-editing technologies, so they are not changing their habits about eating GMO foods.

One of the pioneers of GMOs was Norman Borlaug, PhD, who in the 1950s created a disease-resistant, high-yield, semi-dwarf wheat that fed millions of people in Mexico and South Asia.

GMOs continue to be used to relieve famines and get more crop yield out of available land. In January, Zimbabwe quietly lifted its 12-year-old ban on GMO corn in an effort to avert a severe famine, according to Bloomberg News.

The current and anticipated challenges to the food system arent lost in the U.S. Three federal agencies in March got behind an effort to educate consumers about GMOs. The U.S. FDA, USDA, and EPA launched the Feed Your Mind program, which aims to answer questions about what GMOs are, how and why they are made, how they are regulated, and whether they are healthy and safe.

A GMO is a plant, animal, or microorganism that has had its genetic material modified, including transferring DNA from one organism to another. Apples, potatoes, and soybeans are among the many genetically modified foods that are available in supermarkets.

While foods from genetically engineered plants have been available to consumers since the early 1990s and are a common part of todays food supply, there are a lot of misconceptions about them, FDA Commissioner Stephen Hahn, MD, said when the initiative was launched. This initiative is intended to help people better understand what these products are and how they are made. Genetic engineering has created new plants that are resistant to insects and diseases, led to products with improved nutritional profiles, as well as certain produce that dont brown or bruise as easily.

The COVID-19 pandemic could have a role in consumer awareness of potential food shortages, even though distribution issues may be at the root of the problem now, said Oliver Peoples, PhD, president and CEO of Yield10 Bioscience of Woburn, MA, a company that uses the gene-editing technology CRISPR and other technologies to improve crop yields.

The public has gone to the grocery store and seen empty shelves, including basic staples like meats, chicken, and eggs, he said. This has forced many consumers to try genetically modified products that they might have not typically opted to buy before.

Furthermore, the Millennial and Gen Z generations are making a big difference in the acceptability of food made with technology because they are very focused on climate change and sustainability, said Dr. Peoples.

Marketing company Ketchum found that 77% of Gen Z consumers it polled are likely to try food made with technology and 71% are comfortable with its use to grow food (see Food Tech Consumer Perception table below).

This bodes well for food companies, as Gen Z is the newest generation of food consumers with purchasing power, said Bill Zucker, managing director of food at Ketchum.

By Lori Valigra, journalist based in Harrison, ME. Reach her at valigra@gmail.com.

Read more:
How Receptive are Consumers to Agricultural Biotech? - Food Institute Focus - Food Institute Blog

Read More...

What scientists are learning about COVID-19 from animals – WISHTV.com

June 15th, 2020 6:50 am

INDIANAPOLIS (WISH) Health experts say a vaccine is the worlds best hope to ending the coronavirus pandemic.

And while there are currently dozens of human clinical trials underway, other trials are enlisting animals. Some are house pets, some live in pastures, and others in tropical rain forests.

Ferrets

Ferrets are vulnerable to many respiratory illnesses found in humans, including lung cancer, cystic fibrosis and the novel coronavirus,thus making them great candidates for experimentation, scientists say.

Researchers now know ferrets can contract and transmit COVID-19. This has a lot to do with how the virus enters the body and attacks the lungs. The mechanism mirrors how COVID-19 attaches to human lungs, scientists say.

Scientists from the Commonwealth Scientific and Industrial Research Organization in Australia have started two pre-clinical trials to test a potential COVID-19 vaccine using the animal.

Monkeys

Scientists from The Jenner Institute at Oxford University began working on a coronavirus vaccine back in 2019. While its not for COVID-19, the virus responsible for this pandemic, its very similar.

The vaccine was tested at the National Institutes of Healths Rocky Mountain Laboratory in Montana. Scientists injected six rhesus monkeys with the 2019 vaccine and then exposed them to the novel coronavirus. Less than a month later, all six monkeys showed no signs of COVID-19.

Cows

Researchers are also looking to cows in an effort to develop a treatment. Scientists at SAB Biotherapeutics in South Dakota, through genetic engineering, created an embryo that contains parts of human chromosomes. The embryo is then implanted into the cow.

The resulting calf then grows into what scientists call a genetically humanized cow. The only overlap between the cow and a person is a portion of their immune system.

The genetically humanized cows are then injected with COVID-19. The cows immune system now similar to a persons would then attack the coronavirus. From there, scientists would look to see if the cows develop antibodies against it. The idea is that these antibodies would then be extracted from the cows blood and used as a drug to combat the coronavirus.

Original post:
What scientists are learning about COVID-19 from animals - WISHTV.com

Read More...

Page 497«..1020..496497498499..510520..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick